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ABSTRACT
In Fortaleza, the capital of Ceara State, Brazil, the detection rate of tuberculosis (TB) in 
2018 was 65.5/100,000 inhabitants with a cure rate of 59.1%, which is higher than the country 
average. This study investigated the risk factors associated with drug-resistant tuberculosis 
(DR-TB) and identified the drug-resistance phenotype and resistance-conferring mutations. 
The geographic distribution of DR-TB in Fortaleza, Brazil, was also determined. From 
March 2017 to February 2018, 41 DR-TB isolates and 69 drug-susceptible pulmonary TB 
isolates were obtained from patients seen at a referral hospital in Fortaleza, Brazil. Samples 
were subjected to phenotypic and genetic analysis of resistance; the spatial distribution of 
the participants was also analyzed. Primary resistance was high (50.9%) among participants. 
The following risk factors for DR were identified: being female (p = 0.03), having diabetes 
(p < 0.01), history of previous TB disease (p < 0.01), and the number of intra-domiciliary 
contacts (p < 0.01). Analysis by multiplex allele-specific polymerase chain reaction detected 
mutations in the genes katG (65.8%), rpoB (43.9%), inhA promoter (14.6%), and gyrA 
(9.8%). Sequencing identified mutations in the the genes katG (75.6%), inhA promoter 
(19.5%), rpoB (85.4%), and gyrA (100%). There was no mutation in the rrs gene. Spatial 
analysis showed DR-TB isolates distributed in areas of low socioeconomic status in the city 
of Fortaleza. Our results emphasized the importance of detecting resistance to TB drugs. 
The resistance found in the gene gyrA is of concern due to the high number of pre-extensive 
DR-TB cases in Fortaleza.
KEYWORDS: Mycobacterium tuberculosis. Multidrug-resistant TB. Primary resistance. 
Pre-extensively drug-resistant TB. Risk factors. 
INTRODUCTION
Brazil ranks 20th among the 30 countries responsible for 87% of new cases of 
tuberculosis (TB) globally1. In 2018, there were 72,788 new cases of TB with a case 
detection rate (CDR) of 34.8/100,000 inhabitants2. The World Health Organization 
(WHO) aims to reduce the TB CDR to less than 10.0/100,0001. Ceara State, 
located in the Northeastern region of the country, presented a CDR of 41.8/100,000 
inhabitants, ranking 11th in the number of new cases among Brazilian states. In 
Ceara, new cases of TB mainly occur in Fortaleza, the State capital, including 61% 
of drug-resistant (DR)-TB cases, with an average cure rate of 70.3%, lower than 
the recommended rate of 85% worldwide1,3. Fortaleza is the fifth largest city in the 
country, administratively divided into six regions, with a population of approximately 
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2.6 million people4. In 2010, the Human Development Index 
of Fortaleza was 0.754, ranking 467th among the Brazilian 
municipalities5.
In 2017, the Brazilian Ministry of Health developed 
a national plan to combat TB as a public health problem, 
aiming at eradicating the disease and reducing the 
incidence to less than 10.0/100,000 inhabitants by 20356. 
Brazil has characteristics that favor the transmission of 
the disease, such as a great social inequality and a high 
rate of urbanization. Thus, in order to reduce the number 
of cases of TB, especially the transmission of primary 
resistant species, it is necessary to promote early diagnosis, 
identify socioeconomic and epidemiologic indicators, and 
identify the spatial distribution of clusters of cases. There 
are no reports on the characterization of resistance-related 
mutations against anti-TB drugs in Fortaleza, and also on 
the spatial distribution of cases of DR-TB. 
Resistance to anti-Mycobacterium tuberculosis drugs 
is mainly caused by spontaneous mutations in drug-
directed chromosomal genes or drug-modifying enzyme-
related genes. Genetic studies have shown the presence of 
specific mutations in the genes responsible for conferring 
resistance to routine first-line and second-line anti-TB 
drugs. Mutations in katG and in the regulatory region of 
inhA (inhA-15) account for 42% to 95% and 6% to 43% 
of isoniazid (INH) resistance cases, respectively. For 
rifampicin (RMP), the most common mutation is in the 
resistance-determining region (RDR) of rpoB, with a 95% 
frequency, whereas for streptomycin (STR), most mutations 
(76%) occur in the 16S rRNA gene and the rpsL (52%-59%) 
genes. For quinolones, mutations are found in the genes 
gyrA and gyrB (75-94%). Resistance to ethambutol (EMB) 
is often associated with simultaneous resistance to INH, 
RMP and STR, and mutations in the embCAB gene7.
Rapid diagnosis is required for DR-TB surveillance 
and control. Ideally, we should have a sensitive, rapid, and 
reasonably economical technique that does not require 
complex methods, as most cases of resistance occur in 
underdeveloped countries with limited economic resources. 
Thus, molecular techniques, such as allele-specific 
polymerase chain reaction (PCR) and sequencing, have been 
used in the detection of these mutations and to overcome 
the limitations of phenotypic testing8.
The main objective of this study was to identify 
resistance-related mutations to the main first-line and 
second-line anti-TB drugs in Fortaleza and to compare 
phenotypic tests results (BACTEC Mycobacterial Growth 
Indicator Tube [MGIT] 960) with allele-specific PCR and 
sequencing. We have also investigated the risk factors 
associated with DR-TB and the geographic distribution of 
the study participants.
MATERIALS AND METHODS
This prospective case-control study was conducted from 
March 2017 to February 2018 in Fortaleza, Northeast Brazil. 
The study participants were recruited at the Messejana 
Hospital Dr. Carlos Alberto Studart Gomes, which is a 
reference center for the treatment of DR-TB. This is a 
349-bed teaching hospital in Northeast Brazil, a leading 
hospital for treating patients with lung diseases, including 
DR-TB. On average, Messejana Hospital cares for 2,500 
patients with DR-TB per year, and about 165 patients per 
month. 
For the sample calculation, it was observed that 83 cases 
of multidrug-resistant (MDR)-TB were reported in 2013, 
95 in 2014, 75 in 2015, and 45 cases in 2016. Regarding 
pre-extensively drug-resistant (XDR)-TB, 10 cases were 
reported in 2013, 21 in 2014, 5 in 2015, and 3 cases in 
2016. The sample size for a finite population of at least 
37 participants with DR-TB was estimated using a 95% 
confidence level (α = 0.05), 50% of the population, and 
an error rate of 5%. The equation for the sample size 
calculation was n = [N × z2 × p × (1 − p)]/[d2 × (N − 1) + 
z2 × p × (1 − p)], where N is the total number of new smear-
positive cases registered during one year at the hospital; 
the z value corresponds to the desired confidence level 
(z = 1.95); d is the absolute precision and p is the expected 
proportion of drug resistance in the target population9. The 
calculated sample size was increased by 20% to compensate 
for expected losses. Participants presented respiratory 
symptoms or chest radiography results suggesting 
pulmonary TB, confirmed by a clinical physician10. 
During the nursing appointment and after the laboratory 
confirmation of a new case of TB, participants were invited 
to take part in the study and to answer the questionnaire, 
which included demographic, socioeconomic, clinical, and 
behavioral data.
Patients with pulmonary TB who signed the informed 
consent and were at least 16 years old were included in 
the study. In the case of participants under the age of 18, 
parental or legal guardian consent was also obtained. The 
inclusion criterion of cases was resistance to at least one 
anti-TB drug confirmed by mycobacterial culture. Control 
patients were those with TB susceptible to treatment, as 
confirmed by a negative laboratory result according to the 
national TB program guidelines. The final sample size was 
110 (41 cases and 69 controls). Patients infected with HIV, 
presenting extra-pulmonary TB and those without a fixed 
residence were excluded from the study.
This project was approved by the Ethics Committee 
of the Federal University of Ceara, Fortaleza, Ceara State, 
Brazil (protocol Nº 1.956.894). All participants (and/or legal 
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guardians) signed an informed consent form and authorized 
the sample collections.
Sputum samples were subjected to microscopic 
examination and culture in Löwenstein-Jensen medium. 
M. tuberculosis isolates were tested for susceptibility to 
first-line anti-TB drugs (STR, INH, RMP, and EMB) in an 
automated system (BACTEC MGIT 960)11. The critical 
concentrations of drugs in the medium were as follows: 
STR 1 µg/mL, INH 0.1 µg/mL, RMP 1 µg/mL, and EMB 
5 µg/mL according to WHO guidelines9. Samples were 
incubated until they became positive or for a maximum of 
42 days to deliver a negative result. For DNA extraction, 
samples considered positive were removed from the 
equipment, and sub-cultured in Löwenstein-Jensen medium. 
The sub-cultures were incubated for up to 20 days at 37 °C 
to evaluate possible contaminants. DNA extraction was 
performed as described earlier12.
The multiplex allele-specific (MAS)-PCR protocol 
and primer sequences for the katG315, inhA-15 (inhA 
promoter), rrs A1401G, rpoB codons 516, 526 and 531 as 
well as gyrA D94G were used as described previously13-16. 
Each assay, for each of the genes involved three primers: 
an external forward primer, an external reverse primer and 
an allele-specific internal reverse primer, with the exception 
of the protocol described for the simultaneous analysis of 
rpoB codons 516, 526 and 531, which used a set of four 
primers. All allele-specific primers target the reference 
strain M. tuberculosis H37Rv allele. After amplification, 
PCR products were electrophoresed in 3% agarose gels in 
Tris-borate EDTA buffer at 120 V for 40 min, and visualized 
under ultraviolet light.
The oligonucleotides for Sanger sequencing were 
designed by the authors using the Primer3Plus program 
based on the genomic region of M. tuberculosis H37Rv, 
deposited in GenBank (NCBI: txid83332)17. Table 1 shows 
the primer sequences used for amplification in each of the 
five sequencing assays. PCR products were purified using a 
BigDye Xterminator Purification Kit (Applied Biosystems, 
Thermo Fisher Scientific, Waltham, MA, USA) before 
sequencing in an Applied Biosystems DNA Sequencer. 
Sequences were analyzed using SecScape software 
v.2.7 (Applied Biosystems) and the BioEdit Sequence 
Alignment Editor version 7.2.5 (BioEdit, Carlsbad, CA, 
USA). M. tuberculosis strain H37Rv sequence was used as 
to prototype to align and analyze the obtained sequences.
The addresses of all the participants were geo-referenced 
using MyGeoPosition.com18. The coordinates were entered 
into a Microsoft Excel 2013 datasheet and transferred to 
the ArcGIS 9.3 program (Environmental Systems Research 
Institute, Redlands, CA, USA) for mapping and illustration 
of case contact networks. The ArcMap application provided 
information on maps showing the distribution of geo-
referenced cases in Fortaleza according to drug resistance. 
We used a search radius of 10 km and grid size of 2.5 km.
A bivariate analysis was performed for all the variables 
of interest, for the cases and controls. SSPS v10.0 and 
Epi-info v6.04d were used for analyses. The chi-squared test 
was used to compare the proportions and differences, which 
were considered significant at p ≤ 0.05. The Student’s t test 
was used to compare the averages of continuous variables. 
The Mann-Whitney U test was used to compare data with 
high asymmetry.
RESULTS
The average age of the participants in this study was 
40.5 years (the participants in the control group were 
younger), and almost half of the participants had not been 
previously treated for TB (56/110 or 50.9%). Table 2 presents 
a descriptive statistical analysis of the main characteristics 
Table 1 - Primer sequences used in individual sequencing assays, melting temperature and molecular weight of products.
Primers Sequence (5´- 3´) Tm (°C) Molecular weight (bp)
katG315F GCTTCAAGACGTTCGGGTTC 59.5 840
katG315R GGCAATCTCGGCTTCGC 60.8
-15inhAF CGGGAAGATCCGCGTCG 60.3 806
-15inhAR CTGCCGGAGACCGAACCT 61.3
rpoBF GCGYCGGYCGCTATAAGGTC 60.7 818
rpoBR CGAGACGTCCATGTAGTCCA 58.9
gyrAF CGCAACCCTGCGTTCGAATTG 62.8 809
gyrAR CCTCAACAACRCCGCGCAT 61
rrsF ATAGGCGTTCCCTTGTGGC 60.1 778
rrsR CACAAGAACACGCCACCG 60
bp- base-pair
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of the participants. Diabetes (p < 0.01; odds ratio [OR], 7.4; 
95% confidence interval [CI], 2.4-22.4), history of previous 
disease (p < 0.01; OR, 6.2; 95% CI, 2.6-14.8), and a high 
number of intra-domiciliary contacts (p < 0.01; OR, 3.1; 
95% CI, 1.4-6.8) were the most frequent variables in the case 
group. Female gender was also more frequent among the 
cases (51.2%; p = 0.03). There were no differences between 
cases and controls considering age, occupation, schooling, 
alcohol consumption, use of illicit drugs, psychiatric disorder 
and chronic obstructive pulmonary disease.
From the total of 41 isolates included in the study, 12 
(29.3%) were resistant to only one drug, 14 (34.1%) were 
resistant to two drugs and 15 (36.6%) were resistant to 
three or more drugs. Simultaneous resistance to RMP and 
INH and to all first-line tested drugs (RMP, INH, EMB, 
and STR) were the most frequent (26.8% and 24.4%, 
respectively).
The frequencies of mutations detected by sequencing 
of genes related to INH, RMP, STR, and fluoroquinolone 
(FQ) resistance are shown in Table 3. In relation to INH, 
eight C→T mutations (21.6%, 8/37) were found at position 
15 of the inhA promoter region in the resistant profile 
samples in the BACTEC system, and six were positive in 
MAS-PCR. Regarding the gene katG, the presence of an 
S315T mutation was found in 31 isolates (75.6%). Three 
isolates with an S315T mutation presented a susceptible 
profile in BACTEC system, and 27 of the isolates with the 
same mutation were positive in MAS-PCR.
Mutations in the RDR were found in 35 isolates, of 
which 4 (9.7%) had a susceptible profile in the BACTEC 
system and 18 (43.9%) were positive in MAS-PCR. The 
most frequent mutation was at codon 531 in 17 isolates 
(48.9%), followed by codon 516 in 15 isolates (42.8%) with 
mutations at gAc→gTc (53.4%) and Gac→Tac (46.6%). 
Mutations in codon 531 were found in two isolates with 
susceptible phenotypes.
Table 2 - Demographic and clinical characteristics of the study participants in the city of Fortaleza, from March 2017 to February 2018.
Variables Total N = 110 (%)
Cases 
N = 41 (%)
Controls 
N = 69 (%) pa OR (95% CI)
Age (years) 
Mean (SD) 40.5 (13.4) 41 (11.2) 40 (14.7)
< 39 48 (43.6) 17 (41.5) 31 (44.9) 1
40 - 49 40 (36.4) 15 (36.6) 25 (36.2) 0.84c 0.91 (0.4-2.2)
> 50 22 (20) 9 (21.9) 13 (18.8) 0.66d 0.79 (0.3-2.2)
Gender
Male 68 (61.8) 20 (48.8) 48 (69.6) 0.03 0.4 (0.2-0.9)
Female 42 (38.2) 21 (51.2) 21 (30.4) 1.0
Ocuppation
Unemployed 79 (71.8) 32 (78.1) 47 (68.1) 0.26 1.7 (0.7-4.1)
Employed 31 (28.2) 9 (21.9) 22 (31.9) 1.0
Diabetes
Yes 20 (18.2) 15 (36.6) 5 (7.2) <0.01b 7.4 (2.4-22.4)
No 90 (81.8) 26 (63.4) 64 (92.8) 1
Alcohol use
Yes 63 (57.3) 24 (58.5) 39 (56.5) 0.84 1.1 (0.5-2.4)
No 47 (42.7) 17 (41.5) 30 (43.5) 1
History of previous disease
Yes 54 (49.1) 31 (75.6) 23 (33.3) <0.01b 6.2 (2.6-14.8)
No 56 (50.9) 10 (24.4) 46 (66.7) 1
Number of intradomiciliar contacts
≤ 3 69 (62.7) 19 (46.3) 50 (72.5) <0.01 1
≥ 4 41 (37.3) 22 (53.7) 19 (27.5) 3.1 (1.4-6.8)
Cases: drug-resistant tuberculosis; Controls: drug-susceptible tuberculosis; SD, standard deviation; OR, odds ratio; 95% CI, 95% 
confidence interval. aPearson’s chi square test; bFisher’s exact test; cComparison of 40 to 49 years old and over 50 years old par-
ticipants; dComparison of under 39 years and over 50 years participants.
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No mutations were found at positions 1009 and 1787 
of the rrs gene, and no mutations were detected in the 
samples analyzed by MAS-PCR. However, 43.9% (18/41) 
of these isolates were resistant to STR in the BACTEC 
system. Regarding FQ, mutations associated with a resistant 
phenotype were found in all the samples. Mutations were 
detected at codons 89 (D89A), 90 (A90E and A90V), 
94 (D94G and D94N) and 95 (S95T). Mutations in codon 
95 were the most frequent (29/41; 70.7%), followed by 
codon 90 (10/41; 24.4%), codon 94 (6/41; 14.6%) and 
codon 89 (1/41; 2.4%). MAS-PCR was positive in four of 
the six isolates with mutation in codon 94.
Table 3 - Mutations observed in inhA-15, rpoB, katG, rrs and gyrA genes, phenotypic resistance and MAS-PCR positivity in 41 
resistant isolates of M. tuberculosis.
Drug Mutation by gene location
N (%)
Total of 
Resistant 
samples
Total of 
Susceptible 
samples
Total of 
mutated 
samples a
Resistant with 
mutation
Susceptible 
with mutation MAS-PCR
a
INH 37 (90.1) 4 (9.9)
mabA
-15 position (C/T) 8 (19.5%) 8 (21.6%) 0 6 (14.6)
katG
codon 315 
S315T (aGc/aCc) 31 (75.6) 28 (75.7) 3 (75) 27 (65.8)
RMP 37 (90.6) 4 (9.7)
rpoB 35 (85.4) 18 (43.9)
codon 516 15 (42.8) 15 (100) 0 15 (83.3)
D516Y (Gac/Tac) 7 (46.6) 7 (100) 0
 D516V (gAc/gTc) 8 (53.4) 8 (100) 0
codon 526 3 (8.3) 3 (100) 0 3 (16.7)
H526Y (Cac/Tac) 1 (33.3) 1 (100) 0
H526R (cAc/cGc) 2 (66.7) 2 (100) 0
codon 531 17 (48.9) 15 (88.2) 2 (11.8) 0
S531L (tCg/tTg) 17 (100) 15 (100) 2 (11.8)
AG 18 (43.9) 23 (56.1)
rrs
codon 1401 0 0 0 0
FQ nt nt
gyrA 41 (100)a 4 (9.8)
codon 89 1 (2.4) 0
D89A (gAc/gGg) 1 (2.4)
codon 90 10 (24.4) 0
A90E (gCg/gAg) 2 (4.9)
A90V (gCg/gTg) 8 (19.5)
codon 94 6 (14.6) 4 (100)
D94G (gAc/gGc) 5 (12.2)
D94N (Gac/Aac) 1 (2.4)
codon 95 29 (70.7) 0
S95T (aGc/aCc) 29 (70.7)
aTotal of isolates was used as reference. S: susceptible; R: resistant; MAS-PCR: multiplex allele specific-polymerase chain reaction; 
nt: not tested; INH: isoniazid; RMP: rifampicin; AG: aminoglicosyde; FQ: fluoroquinolona. Amino acids codes: A: alanine; D: aspartic 
acid; E: glutamic acid; F: phenylalanine; G: glycine; H: histidine; L: leucine; N: asparagine; R: arginine; S: serine; T: threonine; V: 
valine; Y: tyrosine.
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A total of 41 samples were analyzed for RMP and 
INH resistance in the BACTEC system and MAS-PCR 
(Table 4). Twenty-eight isolates (75.6%) showed resistance 
to RMP and were positive in MAS-PCR (p < 0.03). Of 41 
samples subjected to rpoB gene sequencing, 94.3% (33/35) 
were resistant according to the BACTEC system and were 
positive by sequencing (p = 1.0). In relation to INH, we 
verified that 97.3% (36/37) of the clinical isolates presented 
resistance in the BACTEC system and were positive in 
MAS-PCR (p < 0.56) corresponding to a sensitivity of 
97.3%. In addition, we verified that 88.9% (32/36) of the 
samples were positive in the BACTEC system and by 
sequencing (p = 0.71).
Forty-three of the isolates were from participants living 
in Fortaleza city; the remaining (n = 6) were from the 
countryside of Ceara State. The spatial analysis (Figure 1) 
showed that DR-TB cases were spread throughout the city, 
predominantly in the Western region. Most of the cases 
were located within administrative regions 1, 5, and 6, 
with 11, 10, and 9 participants with DR-TB, respectively. 
The other administrative regions (2, 3, and 4) had a total 
of eight DR-TB cases. 
DISCUSSION
This study showed that most of the drug-resistant 
participants have not been previously treated (75.6%), and 
all the isolates presented mutation in the gyrA gene. The 
frequency of primary resistance was high in relation to 
that found in Brazil, in Ethiopia and Serbia19-21 and lower 
than the one found in Bangladesh22. The cases of DR-TB 
were spread throughout the city, raising concern about the 
increase in the number of cases bearing primary resistant 
M. tuberculosis.
Regarding the number of intra-domiciliary contacts, 
drug resistance was more frequent among those who 
reported having four or more intra-domiciliary contacts. It 
has already been reported in Amazonas State, Brazil, that 
DR-TB patients have an average of five family contacts23. 
However, a cohort study conducted in 2015 in Lima, Peru, 
found that crowding was associated with a greater incidence 
of secondary cases of TB disease among household contacts 
of drug-susceptible TB patients24. We have found that 
women are at a higher risk of resistance than men. A study 
conducted in Sokobanja, Serbia, found no differences in 
gender between TB-susceptible and DR-TB21, whereas 
others found that males were at higher risk25,26.
We found that diabetes was a comorbidity associated 
with resistance to anti-TB drugs. Data point out to the impact 
of diabetes on the immune system, favoring the bacillus 
survival27. Diabetes causes increased susceptibility to TB 
through several mechanisms, including hyperglycemia 
and cellular insulinopenia, which have indirect effects 
on macrophage and lymphocyte function27,28. Diabetes is 
Table 4 - Contingency analysis between BACTEC MGIT 960 positivity, MAS-PCR assay and genetic sequencing.
Detected mutation
BACTEC MGIT 960
Total R S pa kappa s (%)
N (%) N (%) N (%)
RMP
MAS-PCR
Yes 30 (73.2) 28 (75.6) 2 (50.0) 0.03 0.14 75.68
No 11 (26.8) 9 (24.4) 2 (50.0)
Total 41 (100) 37 (100) 4 (100)
Sequencing 
Yes 35 (85.4) 33 (94.3) 2 (33.3) 1 0.61 94.29
No 6 (14.6) 2 (5.7) 4 (66.7)
Total 41 (100) 35 (100) 6 (100)
INH
MAS-PCR 
Yes 38 (92.7) 36 (97.3) 2 (50.0) 0.56 0.53 97.30
No 3 (7.2) 1 (2.7) 2 (50.0)
Total 41 (100) 37 (100) 4 (100)
Sequencing 
Yes 35 (85.4) 32 (88.9) 3 (60) 0.71 0.27 88.89
No 6 (14.6) 4 (11.1) 2 (40)
Total 41 (100) 36 (100)  5 (100)
RMP: rifampicin; INH: isoniazid; R: resistant; S: susceptible; s: sensitivity. aMcNemar’s Chi-Square test.
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associated with delays in Mycobacterium TB clearance 
during treatment, treatment failures, death, relapse and 
re-infection. Similar to other studies22,29, we have found a 
7.4 times higher risk of MDR-TB among diabetic patients 
with TB.
Mutations in the gyrA gene were also found in all the 
41 samples, constituting the main mechanism of resistance 
to FQ, with specific mutations at codons 89, 90, 94 and 
95. The identification of mutations in molecular markers 
of resistance characterizes these isolates as XDR-TB, 
with resistance to RMP, INH and at least one FQ drug or a 
second-line injectable drug30. Mutation at the S95T position 
of the gyrA gene was the most frequent mutation in our 
samples, followed by the A90V mutation. Other studies 
in China and the United States have reported the D94G 
codon mutation as the most common, ranging from 17.8% 
to 47.6%31-33. Mutations in A90E and S95T codons are not 
associated with resistance to FQs33. The S95T mutation 
has been described as a natural polymorphism (G284C). 
Identification of mutation in the gyrA gene is relevant for 
establishing FQ therapy, as specific mutations differ with 
respect to the minimal inhibitory concentration of ofloxacin 
and moxifloxacin33.
Regarding aminoglycosides, no mutations were found at 
codon 1401 of the rrs gene with 43.9% of isolates resistant 
to STR in the BACTEC system. However, mutations have 
also been described in other genes, such as rpsL and gidB7, 
and other genes related to efflux pumps34.
Our sequencing results showed that the resistant 
phenotype for INH and RMP obtained by the BACTEC 
system could be accurately predicted. These findings are 
useful for estimating the sensitivity of sequencing, as well 
as of MAS-PCR, compared with the phenotypic test used in 
the BACTEC automated system, still considered the gold 
standard. However, as phenotypic tests of FQ resistance 
in Ceara State are not available, only the sensitivity values 
related to INH and RMP were calculated. Differences 
between phenotypic test results and molecular tests 
are explained by the presence of different mutations in 
uninvestigated genomic regions. Therefore, all discordant 
data were re-tested and sequencing data were reviewed. Other 
studies have also reported these disagreements between the 
phenotypic test (gold standard) and the molecular ones and 
have reinforced that phenotypic data should be interpreted 
cautiously in cases of therapeutic failure8,35.
In our study, MAS-PCR had a sensitivity of 75.7% 
and 97.3% to detect mutations in isolates with resistance 
phenotype to RMP and INH, respectively. The approach 
is cost-effective and is a sensitive PCR-based technique 
to identify main mutations. However, it fails to detect 
Figure 1 - Geographic distribution of the drug-resistant tuberculosis isolates in the city of Fortaleza, from March 2017 to February 
2018. () resistance to ≥ 3 anti-TB drugs; () resistance to ≤ 2 anti-TB drugs.
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mutations outside the RDR in rpoB gene and in other genes 
related to drug resistance. Sensitivity can be maximized 
by exploring the other possible targets associated with 
resistance. Although sequencing is a costly and laborious 
process to confirm results, it can be used to diagnose 
drug-resistant isolates with high specificity and efficiency. 
Sequencing can also identify silent mutations that are not 
always related to phenotypic resistance.
Several limitations of this study should be considered 
in the interpretation of results. Firstly, only the Sanger 
sequencing platform was used, which has low genomic 
coverage. Secondly, the EMB-related gene (embB) and 
other alternative genes related to aminoglycoside, INH and 
FQ resistance were not investigated. As resistance to EMB 
is often associated with MDR and XDR resistance, these 
mutations were not investigated. In our study, 11 cases 
of DR-TB were resistant to EMB, and ten isolates had 
simultaneous resistance to INH, RIF and STR, and one 
isolate to INH. Thirdly, the number of patients studied 
was restrict to allow conclusive evidence regarding the 
sensitivity of the tests. In addition, in our study, the patients 
were recruited from only one hospital in Fortaleza that 
is a reference hospital for DR-TB treatment. Despite 
these limitations, the risk factors associated with DR-TB 
provide important information for health policy makers, 
and the molecular diagnosis has proved to be important for 
monitoring resistance in TB, especially in the detection of 
mutations considered as resistance markers.
Regarding the distribution of DR-TB cases, the 
concentration of participants domiciled in the Western part 
of city, in administrative regions 1, 5, and 6, is explained 
by the higher population density in these regions where 
poverty is common. Regions 1, 5, and 6 have the lowest 
average monthly income per person (from USD 121.98 to 
USD 178.8) in Fortaleza36. The richest neighborhoods in the 
city have average monthly incomes between USD 520.51 
and USD 952.41. These poor regions in the city have also 
a high incidence of violence37. Fortaleza had an average 
incidence of 69.4 violent crimes per 100,000 inhabitants in 
2015. The high rate of violent crime was associated with 
low economic development, limited population’s access 
to infrastructure and health services37. Another study, also 
conducted in Fortaleza, reported a concentration of TB 
cases in insecure regions with low socioeconomic status38. 
Other studies conducted in Brazil have also associated a low 
Human Development Index with TB cases39,40.
CONCLUSION
Our study showed a high prevalence of pre-XDR-TB in 
patients with no history of previous treatment in Fortaleza, 
presenting simultaneous resistance to various drugs. We 
have also shown the presence of pre-XDR-TB in geographic 
regions of the city that are associated with poverty and 
violence. We found that genetic sequencing is a useful tool 
for anti-TB drug-resistance surveillance, and molecular data 
should be routinely shared with public health agencies and 
used in conjunction with spatial analyses for the effective 
disease transmission control.
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